No title
Biotech companies on the stock market follow a rigorous clinical process for their product development. The implications of this for investors is an alternative approach to stock valuation that incorporates the uncertainty to the potential future cash flows will be realized. The 3- step clinical process prior to regulatory approval each increase the probability of having drug candidates approved.
